Literature DB >> 30496126

FGF9 inhibits browning program of white adipocytes and associates with human obesity.

Yingkai Sun1, Rui Wang1, Shaoqian Zhao1, Wen Li1, Wen Liu1, Lingyun Tang2, Zhugang Wang2, Weiqing Wang1, Ruixin Liu1, Guang Ning1, Jiqiu Wang1, Jie Hong1.   

Abstract

Browning of white adipose tissue has been proven to be a potential target to fight against obesity and its metabolic commodities, making the exploration of molecules involved in browning process important. Among those browning agents reported recently, FGF21 play as a quite promising candidate for treating obesity for its obvious enhancement of thermogenic capacity in adipocyte and significant improvement of metabolic disorders in both mice and human. However, whether other members of fibroblast growth factor (FGF) family play roles in adipose thermogenesis and obese development is still an open question. Here, we examined the mRNA expression of all FGF family members in three adipose tissues of male C57BL/6 mice and found that FGF9 is highly expressed in adipose tissue and decreased under cold stress. Furthermore, FGF9 treatment inhibited thermogenic genes in the process of beige adipocytes differentiation from stromal vascular fraction (SVF) in a dose-dependent manner. Similar results were obtained with FGF9 overexpression. Consistently, knockdown of FGF9 in SVF cells by using lentiviral shRNA increased thermogenic genes in differentiated beige adipocytes. RNA sequencing analysis revealed a significant increment of hypoxia-inducible factor (HIF) pathway in the early stage of beige adipocytes differentiation under FGF9 treatment, which was validated by real-time PCR. FGF9 expression was increased in subcutaneous WAT of obese human and mice. This study shows that adipose-derived FGF9 play as an inhibitory role in the browning of white adipocytes. Activation of hypoxia signaling at early stage of adipose browning process may contribute to this anti-thermogenic effect of FGF9.

Entities:  

Keywords:  FGF9; HIF1α; browning; obesity

Mesh:

Substances:

Year:  2019        PMID: 30496126     DOI: 10.1530/JME-18-0151

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  7 in total

Review 1.  Latest Advancements on Combating Obesity by Targeting Human Brown/Beige Adipose Tissues.

Authors:  Ruping Pan; Yong Chen
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-04       Impact factor: 6.055

2.  IRX3 Overexpression Enhances Ucp1 Expression In Vivo.

Authors:  Zhiyin Zhang; Qihan Wu; Yang He; Peng Lu; Danjie Li; Minglan Yang; Weiqiong Gu; Ruixin Liu; Jie Hong; Jiqiu Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-10       Impact factor: 5.555

3.  FGF9 Alleviates the Fatty Liver Phenotype by Regulating Hepatic Lipid Metabolism.

Authors:  Fanrong Zhao; Lei Zhang; Menglin Zhang; Jincan Huang; Jun Zhang; Yongsheng Chang
Journal:  Front Pharmacol       Date:  2022-04-20       Impact factor: 5.988

4.  Mechanisms of the Jian Pi Tiao Gan Yin in the treatment of simple obesity revealed by network pharmacology.

Authors:  Minghui Tian; Hua Gao; Hongfei Jiao; Hongbin Tian; Lulu Han; Xiaowan Lin; Gong Cheng; Fenglei Sun; Bo Feng
Journal:  Ann Transl Med       Date:  2022-03

5.  PIEZO1 mechanoreceptor activation reduces adipogenesis in perivascular adipose tissue preadipocytes.

Authors:  C Javier Rendon; Emma Flood; Janice M Thompson; Miguel Chirivi; Stephanie W Watts; G Andres Contreras
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-31       Impact factor: 6.055

6.  Caloric restriction and Roux-en-Y Gastric Bypass promote white adipose tissue browning in mice.

Authors:  D Huang; Z Zhang; Z Dong; R Liu; J Huang; G Xu
Journal:  J Endocrinol Invest       Date:  2021-07-07       Impact factor: 4.256

Review 7.  Thermogenic Fat: Development, Physiological Function, and Therapeutic Potential.

Authors:  Bruna B Brandão; Ankita Poojari; Atefeh Rabiee
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.